Key Highlights

  • USD 0.295: GeoVax Labs' (NASDAQ:GOVX) premarket price on October 6, 2026 after a 7.6 percent fall, about nine months after a 1-for-25 reverse split that took effect on January 9, 2026 to regain Nasdaq compliance.
  • April 2025: the month the BARDA Project NextGen contract for its COVID-19 Vaccine was terminated for convenience, cutting government contract Revenue to USD 2.5 million in 2025 from USD 4.0 million in 2024, per company-related data.
  • USD 21.5 million: the net loss for fiscal 2025 that, with going-concern language and a short cash runway, frames the reliance of GeoVax Labs (NASDAQ:GOVX) on repeated financings at prices close to the market, according to its annual report.
  • Phase 3: the immunobridging trial GeoVax plans for GEO-MVA, its mpox and smallpox vaccine, under European Medicines Agency scientific advice, which allows it to skip earlier phases, with a Partnership and CEPI laboratory network agreement.

Where the Story Stands

GeoVax, based in Atlanta, shifted its focus after the BARDA contract ended in April 2025 toward GEO-MVA, an MVA-based vaccine for mpox and smallpox, and Gedeptin, an oncolytic therapy for head and neck cancer. The European Medicines Agency advised that a Phase 3 immunobridging trial can proceed without Phase 1 and 2 studies. It reports Phase 3 execution activities and has an agreement with CEPI to use a centralized laboratory network. Its lead COVID-19 program, GEO-CM04S1, remains in Phase 2 trials in immunocompromised patients.

The Financing Treadmill

The company has repeatedly raised small amounts: a USD 1 million registered direct offering, a USD 3 million private Placement priced at the market, a USD 3.2 million public offering, and Warrant inducement transactions. It effected 1-for-15 in January 2024 and 1-for-25 in January 2026 splits, plus a 1-for-20 split in 2020. A price near USD 0.295 means Nasdaq's USD 1.00 minimum bid is again an issue. In May 2026 it reported first quarter results highlighting Phase 3 implementation plans.

Why the Shares Slide

After the split the stock fell again, down about 75 percent since the end of 2025 by one estimate earlier in 2026, because each raise adds shares and cash needs recur. The premarket drop of 7.6 percent on October 6 had no identified announcement. Risks include going-concern language, dilution, the Phase 3 funding gap, the loss of government revenue and delisting risk if the price stays below USD 1.00. GeoVax also received a Nasdaq deficiency letter over its bid price before the January split.

Where Things Stand

Possibly, but only if it funds Phase 3 without repeated dilution. GeoVax Labs (NASDAQ:GOVX) has a plausible mpox and smallpox vaccine program with European regulatory guidance and a distribution-relevant CEPI agreement, yet it trades near USD 0.295 after a 1-for-25 split, reported a USD 21.5 million loss for 2025 and has a record of small, dilutive raises. A partner or larger financing would change that. Next catalysts are a partnership, Phase 3 start-up news, a Nasdaq notice and quarterly results, with dates not yet confirmed. Financing terms are the key variable.